Revolution Medicines, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mark A. Goldsmith
- Full Time Employees
- 883
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 700 Saginaw Drive Redwood City CA United States of America 94063
- IPO Date
- Feb 13, 2020
- CIK
- 0001628171
- Website
- revmed.com
- Similar Companies
- Business
- Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for patients with RAS-addicted cancers, which represent approximately 30% of human cancers; its research and development pipeline centers on proprietary RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including the pan-RAS inhibitor daraxonrasib (RMC-6236), the RAS(ON) G12C-selective inhibitor elironrasib (RMC-6291), and the RAS(ON) G12D-selective inhibitor zoldonrasib (RMC-9805). These inhibitors target previously undruggable frontier targets in the RAS pathway and mTOR signaling through tri-complex mechanisms to enhance drug-target engagement and overcome resistance. The company operates primarily in the United States with global clinical development activities and serves patients and healthcare providers in oncology. Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines leverages its RAS(ON) drug discovery platform to advance late-stage programs. In June 2025, the company entered a transformative $2 billion funding arrangement with Royalty Pharma, comprising up to $1.25 billion in synthetic royalty financing (with $250 million upfront) on daraxonrasib and up to $750 million in senior secured debt to support global development, Phase 3 trials in pancreatic cancer and non-small cell lung cancer, commercialization, and pipeline expansion; this partnership enables Revolution Medicines to retain full control over its programs while advancing multiple Phase 3 trial launches. Recent updates include progress on daraxonrasib's Phase 3 readiness and a technology collaboration with Iambic announced in November 2025 to further enhance its RAS inhibitor portfolio.
Company News
Revolution Medicines Got Its Breakthrough—What Moves It Next?
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales.
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results
U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
Why Revolution Medicines May Be Big Pharma's Next Takeover Target
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High – Should You Buy?
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration